Sei Investments Co. Buys 101,542 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sei Investments Co. boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,504,503 shares of the medical equipment provider’s stock after acquiring an additional 101,542 shares during the quarter. Sei Investments Co. owned approximately 0.67% of Hologic worth $108,460,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Brooklyn Investment Group boosted its stake in shares of Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Trivant Custom Portfolio Group LLC boosted its stake in shares of Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares during the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of Hologic by 29.3% in the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 183 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Stephens reaffirmed an “overweight” rating and issued a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Citigroup cut their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Royal Bank of Canada cut their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Finally, Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Shares of HOLX stock opened at $61.47 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company’s 50 day moving average price is $66.06 and its two-hundred day moving average price is $73.99. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.